跳至主要内容
临床试验/NCT00397722
NCT00397722已完成2 期

Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)

GlaxoSmithKline34 个研究点 分布在 7 个国家目标入组 299 人开始时间: 2006年11月9日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
299
试验地点
34
主要终点
Change from randomization on the LSAS Avoidance subscale score at Week 12

研究概览

简要总结

GW876008 is a drug which may change mans reaction to stress, by decreasing the fear, physical and behavior symptoms that people with SocAD experience in social situations.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment

入排标准

年龄范围
18 Years 至 64 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Change from randomization on the LSAS Avoidance subscale score at Week 12

时间窗: Baseline (Day 0) and Week 12

The LSAS consisted of 24 avoidance responses. All individual items were rated on a scale 0 (never) -3 (always) with higher scores indicating more severe avoidance. The LSAS avoidance subscale Score was the sum of each of the 24 individual responses. If at least 22 items of the items making up the subscale of interest were present at a particular time point, the total score was calculated as Sum of non-missing items multiplied with 24/Number of non-missing items. If less than 22 of the items making up the score of interest were available for a participant at a particular time point, the subscale score was not calculated for that time point. . Day 0 was Baseline and change from Baseline was calculated by subtracting Baseline value from Week 12 value. Data for adjusted mean and SE is presented.

Change from randomization on the LSAS Fear subscale score at Week 12

时间窗: Baseline (Day 0) Week 12

The LSAS consisted of 24 fear responses. All individual items were rated on a scale 0 (none) -3 (severe) with higher scores indicating more severe fear. The LSAS fear subscale score was the sum of each of the 24 individual responses. If at least 22 items of the items making up the subscale of interest were present at a particular time point, the subscale score was calculated as Sum of non-missing items multiplied with 24/Number of non-missing items. If less than 22 of the items making up the score of interest were available for a participant at a particular time point, the subscale score was not calculated for that time point. Day 0 was Baseline and change from Baseline was calculated by subtracting Baseline value from Week 12 value. Data for adjusted mean and SE is presented.

Change from randomization in the clinician-administered LSAS total score at the end of the treatment phase (Week 12)

时间窗: Baseline (Day 0) and Week 12

The LSAS is an investigator-rated scale consisting of 48 questions concerning various social situations. The LSAS is the first psychiatric assessment at all post-screening visits. A qualified independent efficacy rater scored the participant's "fear or anxiety" and "avoidance" of social situations on 4-point scale : where, 0= None, 1= Mild, 2= Moderate, 3= Severe. Scores were recorded in participant's source documents. The LSAS total score was the sum of each of the forty-eight individual responses. Day 0 was Baseline and change from Baseline was calculated by subtracting Baseline value from Week 12 value. Data for adjusted mean and SE is presented.

Change from randomization on the Social Avoidance and Distress Scale (SADS) total score at Week 12

时间窗: Baseline (Day 0) and Week 12

The SADS is a 28 item questionnaire. The total score was obtained by summing together the responses for all 28 items from the SADS questionnaire. Each individual item was rated as true or false. One point was given where items 2, 5, 8, 10, 11, 13, 14, 16, 18, 20, 21, 23, 24, 26 were marked as true and 1 point when each of the remaining items were marked as false. This gave a possible range of possible scores from 0 to 28 with higher scores indicating more severe disorder. If at least 26 of the items making up the total score were present at a particular time point, the total score was calculated as Sum of scores for non-missing items multiplied with 28/Number of non-missing items. If less than 26 of the items making up the score of interest were available for a participant at a particular time point, the total score was not calculated for that time point.

次要结局

  • Change from Randomization in vital signs : heart rate(Baseline (Day 0) and up to Week 12)
  • Number of participants with All adverse events (AE) and serious adverse events SAE)(Up to 18 Weeks)
  • Trough Concentration (Ctrough)(Up to Week 12 (pre dose))
  • Number of participants with abnormal electrocardiogram (ECG) findings any time post randomization(Up to Week 12)
  • Number of participants with chemistry data outside the normal range (Any time post-Randomization)(Up to Week 12)
  • Number of participants with hematology data outside the normal range (Any time post-Randomization)(Up to Week 12)
  • Change from Randomization in Vital Signs: systolic and diastolic blood pressure (SBP and DBP)(Baseline (Day 0) Up to Week 12)
  • Exposure at steady state (AUC (0-τ))(Up to Week 12)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (34)

Loading locations...

相似试验